Annual report pursuant to Section 13 and 15(d)

Deferred Royalty Obligation related to the Sale of Future Royalties (Tables)

v3.24.1
Deferred Royalty Obligation related to the Sale of Future Royalties (Tables)
12 Months Ended
Dec. 31, 2023
Deferred Royalty Obligation [Abstract]  
Schedule of Royalty Obligation transaction

The following table shows the activity of the deferred royalty obligation since transaction inception through December 31, 2023:

 

 

December 31,

 

 

 

2023

 

 

 

(in thousands)

 

Proceeds from the sale of future Vaxcyte royalties

 

$

140,000

 

Issuance costs

 

 

(3,792

)

Non-cash interest expense associated with the sale of future Vaxcyte royalties

 

 

12,570

 

Amortization of issuance costs

 

 

336

 

Deferred royalty obligation related to the sale of future Vaxcyte royalties, net

 

$

149,114